This week on Contemporary OBGYN: Oct 17 to Oct 21
A look at what's coming to Contemporary OBGYN this week.
Nifedipine could help reduce severe hypertension in women with preeclampsia
A randomized trial suggests use of intrapartum extended-release nifedipine could help prevent severe hypertension among pregnant individuals with preeclampsia.
Results of the trial, which randomized 110 individuals, suggest use of nifedipine was associated with reducing in intrapartum acute hypertensive therapy among individuals with preeclampsia with severe features, with further analysis pointing to a lower rate of cesarean delivery compared with placebo therapy.
FDA plans to remove hydroxyprogesterone caproate approval
The controversial 17α-hydroxyprogesterone caproate (17-OHPC; Makena) showed to be ineffective at preventing preterm birth, according to briefing documents.
The United States Food and Drug Administration (FDA) is calling for withdrawal of the approval for 17α-hydroxyprogesterone caproate (17-OHPC; Makena) after briefing documents were released ahead of a 3-day advisory committee meeting.
NPWH 2022: Infertility care
Tamara Tobias, ARNP, WHNP-BC recently led a lecture at during the Nurse Practitioners in Women’s Health (NPWH) 25th Annual Premier Women’s Health Conference, held in Houston, Texas from September 28 to October 2, 2022. The lecture included several case studies and highlighted key takeaways from each.
Check back soon for additional updates!
SKYLIGHT trials confirm safety and efficacy of fezolinetant against sleep disturbances
September 13th 2024At the 2024 Annual Meeting of The Menopause Society, the positive safety and efficacy data of fezolinetant against sleep disturbances from the SKYLIGHT 1 and 2 trials was presented.
Read More
